Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
Latest Information Update: 20 Jun 2023
At a glance
- Drugs HRS 5635 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 15 Jun 2023 Planned number of patients changed from 80 to 85.
- 15 Jun 2023 Status changed from not yet recruiting to recruiting.
- 18 Apr 2023 New trial record